BiotechTube

Rexlemestrocel-L + Rexlemestrocel-L + HA Mixture + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Degenerative Disc Disease

Conditions

Degenerative Disc Disease

Trial Timeline

Mar 6, 2015 → Jun 15, 2021

NCT ID
NCT02412735

About Rexlemestrocel-L + Rexlemestrocel-L + HA Mixture + Placebo

Rexlemestrocel-L + Rexlemestrocel-L + HA Mixture + Placebo is a phase 3 stage product being developed by Mesoblast for Degenerative Disc Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02412735. Target conditions include Degenerative Disc Disease.

What happened to similar drugs?

1 of 5 similar drugs in Degenerative Disc Disease were approved

Approved (1) Terminated (1) Active (3)
✅PimavanserinAcadia PharmaceuticalsApproved
❌LatozinemabAlectorPhase 3
🔄Pimavanserin + PlaceboAcadia PharmaceuticalsPhase 3
🔄PimavanserinAcadia PharmaceuticalsPhase 3
🔄Rexlemestrocel-L + HA mixture + SalineMesoblastPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02412735Phase 3Completed

Competing Products

17 competing products in Degenerative Disc Disease

See all competitors
ProductCompanyStageHype Score
LatozinemabAlectorPhase 3
22
YH14618 + YH14618 + YH14618 + PlaceboYuhanPhase 1/2
32
Placebo + YH14618YuhanPhase 2
35
Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial CellsAstellas PharmaPhase 1/2
39
ONO-2808 + PlaceboOno PharmaceuticalPhase 1
29
Pimavanserin + PlaceboAcadia PharmaceuticalsPhase 3
37
PimavanserinAcadia PharmaceuticalsApproved
47
PimavanserinAcadia PharmaceuticalsPhase 3
37
Lumbar Interbody Fusion with Autograft + Lumbar Interbody Fusion with NeoFuse + Lumbar Interbody Fusion with NeoFuseMesoblastPhase 2
29
NeoFuseMesoblastPhase 2
29
Rexlemestrocel-L + HA mixture + SalineMesoblastPhase 3
41
Single Dose MPCs Injection + Single Dose MPCs InjectionMesoblastPhase 2
29
NeoFuseMesoblastPhase 1/2
26
NeoFuseMesoblastPhase 1/2
26
PLF with NeoFuse + PLF with NeoFuse + PLF with NeoFuseMesoblastPhase 1/2
18
Use iliac bone graft + use bone morphogenetic protein + use bone derived allograft MSCs + Use adipose tissue derived MSCs + Use amnion/placental derived MSCsBrain BiotechPhase 2/3
28
Blood sampling, skin biopsy, excreta sampling, lumbar punctureBrain BiotechPre-clinical
23